The finalization of the consent decree removes a significant regulatory uncertainty for Philips, particularly for its Philips Respironics operations in the US. By providing a clear path for compliance and business restoration, this development is likely to be viewed positively by investors. The confirmation that the financial outlook for 2023-2025 remains unchanged despite this decree suggests that Philips has effectively managed the potential impacts, reinforcing investor confidence in the company's stability and regulatory compliance strategy.